Drug intelligence / Profile preview

RG6913

Development stage: Unknown
Lead developer: Roche
Administration: Intravitreal

Overview

RG6913 is an investigational new molecular entity (NME) being developed by Roche (specifically through its Pharma Research and Early Development, pRED, division) and its subsidiary Genentech for the treatment of diabetic macular edema (DME). It is currently in Phase 1 clinical development. The exact mechanism of action and molecular target of RG6913 have not been publicly disclosed.

Beyond the preview

Go deeper on RG6913.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RG6913.

Explore the full profile